Related Experiment Video
Updated: May 6, 2026
Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
Exploring the Role of ADCs in Brain Metastases and Primary Brain Tumors: Insight and Future Directions
Francesco Bruzzone1,2, Chiara Barigazzi1,2, Antonio Di Muzio1,2
1Department of Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy.
Abstract:
Primary and secondary brain tumors have always been a challenge due to their high morbidity and poor prognosis. The incidence of brain metastasis is also increasing with the advent of effective new treatments. Traditional systemic treatments have historically had limited success, partly due to poor central nervous system (CNS) penetration. However, the advent in recent decades of new therapies that have shown high encephalic response rates are challenging this paradigm. ADCs represent a new class of compounds revolutionizing cancer treatment with high systemic response rates and lower toxicities. The continuing evolution of ADCs has shown that certain structural features such as payload, linker, and drug-to-antibody ratio (DAR) are essential in determining their efficacy at the encephalic level, and some ADCs have started to exhibit promising efficacy in treating primary and secondary brain tumors. Unfortunately, most patients with untreated encephalic metastases are excluded from clinical trials, with data primarily from retrospective studies or post hoc analyses. This review describes the early signs of ADC efficacy in brain tumors, the role of complementary treatments like radiation therapy, and critical points to improve ADC efficacy in brain malignancies.
Insights
Antibody-drug conjugates (ADCs) show promise for treating brain tumors, overcoming challenges of traditional therapies. Optimizing ADC structure is key to improving efficacy in brain malignancies.
Area of Science:
- Oncology
- Neuro-oncology
- Pharmacology
Background:
- Primary and secondary brain tumors present significant challenges with high morbidity and poor prognosis.
- Brain metastasis incidence is rising, necessitating novel treatment strategies.
- Traditional systemic therapies have limited efficacy due to poor central nervous system (CNS) penetration.
Purpose of the Study:
- To review the emerging efficacy of antibody-drug conjugates (ADCs) in treating primary and secondary brain tumors.
- To discuss the role of complementary treatments, such as radiation therapy, in enhancing ADC effectiveness.
- To identify critical factors for improving ADC performance in brain malignancies.
Main Methods:
- Review of current literature on ADCs in brain tumor treatment.
- Analysis of factors influencing ADC efficacy, including payload, linker, and drug-to-antibody ratio (DAR).
- Examination of data from retrospective studies and post hoc analyses due to clinical trial exclusions.
Main Results:
- ADCs are a new class of compounds demonstrating high systemic response rates and reduced toxicity.
- Certain ADCs show promising efficacy in treating primary and secondary brain tumors.
- Structural features of ADCs significantly impact their effectiveness in the brain.
Conclusions:
- ADCs represent a revolutionary approach to cancer treatment with potential for brain tumor therapy.
- Further research and optimization of ADCs are needed to overcome challenges in treating brain malignancies.
- Complementary treatments alongside ADCs may enhance overall therapeutic outcomes.
More Related Videos
09:17Longitudinal Intravital Imaging of Brain Tumor Cell Behavior in Response to an Invasive Surgical Biopsy
Published on: May 3, 2019
13:12Translational Brain Mapping at the University of Rochester Medical Center: Preserving the Mind Through Personalized Brain Mapping
Published on: August 12, 2019
